| Subject: | FDA Notifies Healthcare Professionals of Required Labeling Changes for Immunosuppressant Drugs |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 14 Jul 2009 - 02:00 pm |
| The Food and Drug Administration (FDA) is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy. The immunosuppressant drugs are:Sirolimus (marketed as Rapamune)Cyclosporine (marketed as Sandimmune and generics)Cyclosporine modified (marketed as Neoral and generics)Mycophenolate mofetil... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate notification of regulatory body legislation impacting the healthcare industry, helping you to meet regulatory compliance. Subscribers are notified of any new or revised regulations, provided with a summary of the regulation, followed by an implementation action plan and/or policy. Designed as an e-mail "push" method for rapid customer notification of healthcare compliance issues, paired with interpretative analysis and practical application, the StayAlert!® Virtual Compliance Administrator™ saves you time and money. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
